Clayton Dehn will lead the expansion of Celerion’s capabilities that support early proof-of-concept in the development of diabetes, obesity, metabolic and cardio-metabolic interventions, following his appointment as Executive Director, Metabolic Diseases at the firm.
Within the metabolic disease area, the glucose clamp measures insulin sensitivity, beta cell sensitivity, and characterisation of the time-action profiles of insulin products. It is an intricate yet powerful, highly sensitive, well established technique that can enhance the value of early clinical research efforts in the development of agents for the treatment of both Type 1 and Type 2 diabetes. Dehn has experience in conducting thousands of glucose clamps and brings his substantial expertise in a variety of metabolic research tools to Celerion.
Dehn joins Celerion with 15 years of experience in drug development. He has led successful metabolic programmes at two leading Contract Research Organisations (CROs), and was also Director of Clinical Research and Development at a start-up biotech company developing investigational devices, techniques and compounds for use in assisted reproduction.
